Supplementary Table 6 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal CancerCaroline Even,Hung-Ming Wang,Shau-Hsuan Li,Roger K-C Ngan,Arunee Dechaphunkul,Li Zhang,Chia-Jui Yen,Po Chung Chan, Somvilai Chakrabandhu,Brigette B.Y. Ma,Suebpong Tanasanvimon,Victor H.F. Lee,Pei-Jen Lou,Zujun Li,Alexander I. Spira,Ammar Sukari,Joël Guigay,Steven McCune, Juan Gonzalez-Maffe,Sebastian Szpakowski,Yao Yao,Hongzi Liang,Jennifer Mataraza,Romain Séchaud,Luigi Manenti,Darren W-T. Limcrossref（2023）引用 0|浏览35暂无评分摘要Supplemental Table S6. Adverse events of special interest (patients treated with spartalizumab)更多查看译文AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
